---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070899"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:57:41.928754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ARS Pharma Q1 neffy revenue $7.8M, net loss $33.9M; commercial progress with 5,000+ prescribers

## Summary
- Net product revenue of $7.8M from neffy; total revenue $8.0M; net loss $33.9M ($0.35 per share).
- Cash, equivalents and investments $275.7M; company says runway adequate for over three years.
- More than 5,000 HCPs prescribed neffy; co-promotion with ALK expands reach to ~20,000 HCPs including pediatricians.
- 57% commercial coverage secured; neffy 1mg now available for children 4+ weighing 15-30 kg.
- Regulatory decisions expected mid-2025 in UK, year-end in Canada; German launch mid-2025.

## SEC filing metadata
- accession: 0000950170-25-070899
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/0000950170-25-070899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000095017025070899/spry-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070899
- JSON: https://secwatch.observer/filing/0000950170-25-070899.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.